Search
Close this search box.
Search
Close this search box.

Your Clinical Trial Labeling: Sturdy Footing or Achilles Heel?

How One Small Oversight Brought Down Greece’s Greatest Warrior

Most people are familiar with the story of Achilles and his one point of weakness that led to his demise.  In Homer’s epic poem the “Iliad”, Achilles, Greece’s bravest and strongest warrior, is finally done in when an arrow shot by Paris is guided into his heel by a vengeful Apollo.  In typical Homer fashion there’s a long backstory (we all remember our freshman year Western Civ lecture classes) of politics, meddling gods, broken promises, and lots and lots of revenge-fueled bloodshed.  

What many people may not recall however, is the reason Achilles’ heel was vulnerable.  His mother Thetis made one small error when dipping him in the river Styx to make him invulnerable to mortal injury.  She held him by his foot while dipping him into the river, so his heel was never touched by the water’s magical powers.1  

That one seemingly small detail led to the downfall of Greece’s greatest hero.  In much the same way an error in what may seem like a small part of your clinical trial, labeling, can have catastrophic impact and potentially lead to the downfall of your greatest planned achievements.   

In this blog post, we delve into the world of clinical trial labeling. We’ll discuss its importance in clinical trials, define what labeling errors are, and illustrate the potentially far-reaching impact mistakes in labeling can have on your trial.

The Importance of Quality in Clinical Trial Labeling

The importance of quality in clinical trial labeling as a key component of clinical trial packaging cannot be overstated. Clinical trial labels serve as a primary source of critical information for both administrators and participants, ensuring the accurate identification, dosage, and administration of investigational drugs. Booklet labels for clinical trials play an especially vital role as trials become increasingly more global in scope.

Errors in labeling can jeopardize participant safety, compromise the integrity of trial data, and result in significant regulatory and financial consequences. Given the high stakes, ensuring meticulous accuracy and clarity in labeling is paramount.

What Constitutes a Labeling Error? 

Labeling errors in clinical trials can range from minor typos to significant inaccuracies. They could involve incorrect drug names, wrong dosages, misprinted expiry dates, unclear instructions, or even labels that peel off or become illegible over time. Managing this complexity is especially important for open label clinical trials. 

These errors can have far-reaching consequences for pharmaceutical organizations and clinical research sponsors, including loss of time and resources, financial losses, and reputational damage. To ensure that labeling is done correctly in every stage of a trial, sponsors must have a consistent process for labeling that is both compliant with laws and regulations, as well as efficient.

 

The Domino Effect: How Labeling Errors Can Impact Pharmaceutical Clinical Trials

The Ripple Effect of Labeling Errors

Labeling errors frequently contribute to clinical trial delays, causing a significant increase in both time and costs. A study by the Tufts Center for the Study of Drug Development (CSDD) found that 15 to 25 percent of clinical trial delays are related to labeling issues. This can result in up to a 10-week delay, leading to potential financial losses of up to $8 million per day for a high-profile clinical trial.2 

Furthermore, for every day a trial is delayed, it can result in one less day of patent protection, affecting the overall return on investment for the product. When labeling errors creep into clinical trials, they can trigger a chain reaction of negative consequences. These include:

Compromised Patient Safety

The most immediate and concerning impact of labeling errors is on patient safety. Adverse impacts on clinical trial participants due to labeling errors can be serious and far-reaching. Firstly, incorrect labeling could lead to misadministration of the drug, potentially causing unexpected side effects or compromised efficacy. It’s estimated that labeling errors contribute to approximately 10% of serious adverse events in clinical trials3.

Secondly, delays caused by labeling errors can prolong trial duration, exposing participants to extended periods of uncertainty and potential risks. This can also lead to increased dropout rates, with an estimated 30% of participants in lengthy trials discontinuing their involvement due to such delays. Furthermore, the reputational damage inflicted on trial organizers from labeling errors can undermine trust, potentially making participant recruitment more challenging for future trials.

Skewed Trial Results

Labeling errors in clinical trials can potentially introduce biases or inaccuracies in the collected data, thereby affecting the trial’s validity and reliability. Some examples of skewed data that can be caused by labeling errors include:

  1. Protocol Deviations / Non-Adherence: If participants don’t follow the instructions correctly due to labeling errors, it can lead to deviations from the protocol.
  2. Dosing Inaccuracies: Incorrect dosing information on labels can lead to overdosing or underdosing.
  3. Loss of Data: Participants who are administered incorrect doses or instructions might have to be excluded from the final analysis.
  4. Unequal Distribution: If labeling errors disproportionately affect one arm of a trial (for example, the treatment group but not the control group), it can introduce bias.
  5. Incorrect Data Recording: Labeling errors might result in incorrect recording of data, either by trial participants in the case of self-reporting or by clinical staff.
  6. Time-to-Event Data: If the treatment schedule is disrupted by labeling errors, it can affect time-to-event data (like survival or time to progression).
  7. Quality of Life or Patient-Reported Outcomes: Labeling errors can indirectly impact patient-reported outcomes if, for example, patients experience anxiety or lose trust in the trial due to the errors.

 

Regulatory Sanctions

Regulatory bodies like the FDA and EMA have stringent guidelines for clinical trial labeling. Non-compliance due to labeling errors can attract penalties, including fines and warnings. In severe cases, it could lead to suspension or termination of the trial. Regulatory sanctions may include:

  1. Requirement for Corrective Actions: Regulatory bodies might mandate specific corrective actions, such as re-labeling, additional monitoring, or participant notifications.
  2. Financial Penalties: Depending on the jurisdiction and severity of the error, monetary fines can be imposed.
  3. Hold on the Clinical Trial: The regulatory agency can place the trial on hold, preventing the recruitment of new participants or the continuation of treatment for current participants until the issue is resolved.
  4. Rejection or Delay of Drug Approval: If the labeling errors are deemed significant, the regulatory agency might reject or delay approval of the investigational drug, requiring additional studies or remediation before reconsideration.
  5. Mandated Audits: The regulatory agency might require third-party audits of the sponsor’s processes to ensure compliance with regulations and guidelines.
  6. Suspension or Revocation of Investigational New Drug (IND) or Clinical Trial Authorization: Serious violations might lead to the suspension or revocation of the authorization to conduct the trial.
  7. Criminal Charges: In extreme cases, especially if there’s evidence of willful negligence or intent to deceive, individuals or organizations may face criminal charges.
  8. Loss of Good Manufacturing Practice (GMP) or Good Clinical Practice (GCP) Certification: Regulatory bodies may withdraw certifications if they find that the sponsor or manufacturing site doesn’t adhere to best practices, which could impact other products or trials not directly related to the labeling error.
  9. Increased Scrutiny: Future submissions or applications from the sponsor might be subject to increased scrutiny or additional requirements, leading to longer review times and added costs.

 

Damaged Reputation

Reputational damage to sponsors due to poor quality in clinical trial labeling or related aspects of a trial can have far-reaching consequences. These errors can raise questions about their professionalism and attention to detail, creating mistrust among patients, healthcare professionals, and regulators.

Here are some general consequences and effects of such reputational damages, even if not solely tied to labeling:

  1. Loss of Trust: Clinical trial participants, healthcare professionals, investors, and the general public may lose trust in the sponsor or CRO if they believe that the organization cannot manage fundamental aspects of a trial like labeling properly.
  2. Decreased Stock Value: For publicly-traded companies, significant negative press or regulatory sanctions can lead to a drop in stock prices, reflecting decreased investor confidence.
  3. Difficulty in Recruitment: Future clinical trial recruitment might be hampered if potential participants are wary of the sponsor’s or CRO’s competence.
  4. Regulatory Scrutiny: A reputation for poor quality can lead to increased scrutiny from regulatory bodies, potentially resulting in longer review times or more frequent audits.
  5. Competitive Disadvantage: Competitors might leverage one company’s missteps to position themselves as more reliable or trustworthy.
  6. Strained Relationships: Collaborative partners, vendors, or other stakeholders might reconsider their association with a company perceived as careless or negligent.
  7. Legal Consequences: A tarnished reputation can make a company more vulnerable to lawsuits from participants, investors, or other stakeholders.

 

Financial Consequences

Finally, labeling errors can have significant financial implications. They can lead to costly recalls, waste of valuable trial material, and delays that extend the trial duration. Plus, potential regulatory fines and the cost of rectifying errors can add to the financial burden. Potential financial repercussions that could arise from such errors include:

  1. Regulatory Fines and Penalties: Regulatory bodies might impose financial penalties for non-compliance, especially if labeling errors pose a risk to participant safety or trial integrity.
  2. Cost of Remediation: Correcting the labeling error will involve costs, including re-labeling, re-distribution of materials, and potentially re-manufacturing in severe cases.
  3. Delay in Drug Development Timeline: Delays due to halted trials, regulatory holds, or additional studies can result in considerable added costs and lost opportunities, especially if it means delaying a drug’s entry to the market.
  4. Litigation and Legal Fees: If participants or other stakeholders are harmed or perceive negligence due to labeling errors, they might initiate legal actions against the sponsor or CRO. This can lead to legal defense costs, potential settlements, or compensations.
  5. Cost of Increased Monitoring: Labeling errors might necessitate additional medical monitoring or care for trial participants, adding to the trial budget.
  6. Loss of Investment: Negative perceptions or doubts about the competence of a sponsor or CRO might lead to a loss of current or potential investment, impacting liquidity and R&D capabilities.
  7. Cost of Public Relations and Reputation Management: Addressing negative publicity or restoring reputation may involve hiring PR firms, running new communication campaigns, or other measures that come with their own costs.
  8. Additional Regulatory Submission Fees: If there’s a need to submit additional data or modifications due to labeling errors, it might come with additional regulatory submission fees.
  9. Lost Revenue: In cases where the error affects a trial’s outcome or delays the approval of a market-ready drug, lost revenue from sales can be significant, especially if the drug in question is expected to be a blockbuster.
  10. Termination of Partnership Agreements: If the sponsor or CRO has partnerships or agreements with other entities (like co-development or licensing agreements), severe errors might lead to renegotiations or terminations.

  

While not all of these consequences can be attributed to labeling errors directly, they illustrate the potential repercussions of any missteps. It underscores the importance of attention to detail, quality control, and robust risk management strategies in all aspects of clinical trials, including labeling.

Conclusion

There is no doubt the world of clinical trials labeling is complex and there is no room for error when it comes to managing the safety, financial, and reputational risks that are at stake. Working with a proven, knowledgeable, and experienced labeling partner can help assure your project meets the high-quality standards required for a successful trial.

In this post we’ve defined what clinical labels are, looked at the importance of quality in clinical trial labeling, and the ramifications of errors caused by poor quality or lack of attention to detail. In our next post we’ll dive deeper into the challenges of getting clinical trial labeling right and discuss strategies for assuring your project is a success.

In the meantime, you can learn more about the different applications of clinical trial label booklets here. 

 
1 https://www.history.com/topics/ancient-greece/achilles
2 https://www.centerwatch.com/articles/25453-mid-study-updates-delay-trials-at-least-a-month-csdd-report-finds
3 https://www.federalregister.gov/documents/2021/03/16/2021-05370/potential-medication-error-risks-with-investigational-drug-container-labels-public-meeting-request

Written By:

Category:

Posted On:

Graphic Designer Guide

When it comes to clinical trials, the importance of precision and accuracy cannot be overstated. Every detail counts, and this extends into what may seem like the minutiae of trial management: the labeling of clinical trial materials.

Read More

Written By:

Category:

Posted On:

Updated On:

How One Small Oversight Brought Down Greece’s Greatest Warrior

Most people are familiar with the story of Achilles and his one point of weakness that led to his demise.  In Homer’s epic poem the “Iliad”, Achilles, Greece’s bravest and strongest warrior, is finally done in when an arrow shot by Paris is guided into his heel by a vengeful Apollo.  In typical Homer fashion there’s a long backstory (we all remember our freshman year Western Civ lecture classes) of politics, meddling gods, broken promises, and lots and lots of revenge-fueled bloodshed.  

What many people may not recall however, is the reason Achilles’ heel was vulnerable.  His mother Thetis made one small error when dipping him in the river Styx to make him invulnerable to mortal injury.  She held him by his foot while dipping him into the river, so his heel was never touched by the water’s magical powers.1  

That one seemingly small detail led to the downfall of Greece’s greatest hero.  In much the same way an error in what may seem like a small part of your clinical trial, labeling, can have catastrophic impact and potentially lead to the downfall of your greatest planned achievements.   

In this blog post, we delve into the world of clinical trial labeling. We’ll discuss its importance in clinical trials, define what labeling errors are, and illustrate the potentially far-reaching impact mistakes in labeling can have on your trial.

The Importance of Quality in Clinical Trial Labeling

The importance of quality in clinical trial labeling as a key component of clinical trial packaging cannot be overstated. Clinical trial labels serve as a primary source of critical information for both administrators and participants, ensuring the accurate identification, dosage, and administration of investigational drugs. Booklet labels for clinical trials play an especially vital role as trials become increasingly more global in scope.

Errors in labeling can jeopardize participant safety, compromise the integrity of trial data, and result in significant regulatory and financial consequences. Given the high stakes, ensuring meticulous accuracy and clarity in labeling is paramount.

What Constitutes a Labeling Error? 

Labeling errors in clinical trials can range from minor typos to significant inaccuracies. They could involve incorrect drug names, wrong dosages, misprinted expiry dates, unclear instructions, or even labels that peel off or become illegible over time. Managing this complexity is especially important for open label clinical trials. 

These errors can have far-reaching consequences for pharmaceutical organizations and clinical research sponsors, including loss of time and resources, financial losses, and reputational damage. To ensure that labeling is done correctly in every stage of a trial, sponsors must have a consistent process for labeling that is both compliant with laws and regulations, as well as efficient.

 

The Domino Effect: How Labeling Errors Can Impact Pharmaceutical Clinical Trials

The Ripple Effect of Labeling Errors

Labeling errors frequently contribute to clinical trial delays, causing a significant increase in both time and costs. A study by the Tufts Center for the Study of Drug Development (CSDD) found that 15 to 25 percent of clinical trial delays are related to labeling issues. This can result in up to a 10-week delay, leading to potential financial losses of up to $8 million per day for a high-profile clinical trial.2 

Furthermore, for every day a trial is delayed, it can result in one less day of patent protection, affecting the overall return on investment for the product. When labeling errors creep into clinical trials, they can trigger a chain reaction of negative consequences. These include:

Compromised Patient Safety

The most immediate and concerning impact of labeling errors is on patient safety. Adverse impacts on clinical trial participants due to labeling errors can be serious and far-reaching. Firstly, incorrect labeling could lead to misadministration of the drug, potentially causing unexpected side effects or compromised efficacy. It’s estimated that labeling errors contribute to approximately 10% of serious adverse events in clinical trials3.

Secondly, delays caused by labeling errors can prolong trial duration, exposing participants to extended periods of uncertainty and potential risks. This can also lead to increased dropout rates, with an estimated 30% of participants in lengthy trials discontinuing their involvement due to such delays. Furthermore, the reputational damage inflicted on trial organizers from labeling errors can undermine trust, potentially making participant recruitment more challenging for future trials.

Skewed Trial Results

Labeling errors in clinical trials can potentially introduce biases or inaccuracies in the collected data, thereby affecting the trial’s validity and reliability. Some examples of skewed data that can be caused by labeling errors include:

  1. Protocol Deviations / Non-Adherence: If participants don’t follow the instructions correctly due to labeling errors, it can lead to deviations from the protocol.
  2. Dosing Inaccuracies: Incorrect dosing information on labels can lead to overdosing or underdosing.
  3. Loss of Data: Participants who are administered incorrect doses or instructions might have to be excluded from the final analysis.
  4. Unequal Distribution: If labeling errors disproportionately affect one arm of a trial (for example, the treatment group but not the control group), it can introduce bias.
  5. Incorrect Data Recording: Labeling errors might result in incorrect recording of data, either by trial participants in the case of self-reporting or by clinical staff.
  6. Time-to-Event Data: If the treatment schedule is disrupted by labeling errors, it can affect time-to-event data (like survival or time to progression).
  7. Quality of Life or Patient-Reported Outcomes: Labeling errors can indirectly impact patient-reported outcomes if, for example, patients experience anxiety or lose trust in the trial due to the errors.

 

Regulatory Sanctions

Regulatory bodies like the FDA and EMA have stringent guidelines for clinical trial labeling. Non-compliance due to labeling errors can attract penalties, including fines and warnings. In severe cases, it could lead to suspension or termination of the trial. Regulatory sanctions may include:

  1. Requirement for Corrective Actions: Regulatory bodies might mandate specific corrective actions, such as re-labeling, additional monitoring, or participant notifications.
  2. Financial Penalties: Depending on the jurisdiction and severity of the error, monetary fines can be imposed.
  3. Hold on the Clinical Trial: The regulatory agency can place the trial on hold, preventing the recruitment of new participants or the continuation of treatment for current participants until the issue is resolved.
  4. Rejection or Delay of Drug Approval: If the labeling errors are deemed significant, the regulatory agency might reject or delay approval of the investigational drug, requiring additional studies or remediation before reconsideration.
  5. Mandated Audits: The regulatory agency might require third-party audits of the sponsor’s processes to ensure compliance with regulations and guidelines.
  6. Suspension or Revocation of Investigational New Drug (IND) or Clinical Trial Authorization: Serious violations might lead to the suspension or revocation of the authorization to conduct the trial.
  7. Criminal Charges: In extreme cases, especially if there’s evidence of willful negligence or intent to deceive, individuals or organizations may face criminal charges.
  8. Loss of Good Manufacturing Practice (GMP) or Good Clinical Practice (GCP) Certification: Regulatory bodies may withdraw certifications if they find that the sponsor or manufacturing site doesn’t adhere to best practices, which could impact other products or trials not directly related to the labeling error.
  9. Increased Scrutiny: Future submissions or applications from the sponsor might be subject to increased scrutiny or additional requirements, leading to longer review times and added costs.

 

Damaged Reputation

Reputational damage to sponsors due to poor quality in clinical trial labeling or related aspects of a trial can have far-reaching consequences. These errors can raise questions about their professionalism and attention to detail, creating mistrust among patients, healthcare professionals, and regulators.

Here are some general consequences and effects of such reputational damages, even if not solely tied to labeling:

  1. Loss of Trust: Clinical trial participants, healthcare professionals, investors, and the general public may lose trust in the sponsor or CRO if they believe that the organization cannot manage fundamental aspects of a trial like labeling properly.
  2. Decreased Stock Value: For publicly-traded companies, significant negative press or regulatory sanctions can lead to a drop in stock prices, reflecting decreased investor confidence.
  3. Difficulty in Recruitment: Future clinical trial recruitment might be hampered if potential participants are wary of the sponsor’s or CRO’s competence.
  4. Regulatory Scrutiny: A reputation for poor quality can lead to increased scrutiny from regulatory bodies, potentially resulting in longer review times or more frequent audits.
  5. Competitive Disadvantage: Competitors might leverage one company’s missteps to position themselves as more reliable or trustworthy.
  6. Strained Relationships: Collaborative partners, vendors, or other stakeholders might reconsider their association with a company perceived as careless or negligent.
  7. Legal Consequences: A tarnished reputation can make a company more vulnerable to lawsuits from participants, investors, or other stakeholders.

 

Financial Consequences

Finally, labeling errors can have significant financial implications. They can lead to costly recalls, waste of valuable trial material, and delays that extend the trial duration. Plus, potential regulatory fines and the cost of rectifying errors can add to the financial burden. Potential financial repercussions that could arise from such errors include:

  1. Regulatory Fines and Penalties: Regulatory bodies might impose financial penalties for non-compliance, especially if labeling errors pose a risk to participant safety or trial integrity.
  2. Cost of Remediation: Correcting the labeling error will involve costs, including re-labeling, re-distribution of materials, and potentially re-manufacturing in severe cases.
  3. Delay in Drug Development Timeline: Delays due to halted trials, regulatory holds, or additional studies can result in considerable added costs and lost opportunities, especially if it means delaying a drug’s entry to the market.
  4. Litigation and Legal Fees: If participants or other stakeholders are harmed or perceive negligence due to labeling errors, they might initiate legal actions against the sponsor or CRO. This can lead to legal defense costs, potential settlements, or compensations.
  5. Cost of Increased Monitoring: Labeling errors might necessitate additional medical monitoring or care for trial participants, adding to the trial budget.
  6. Loss of Investment: Negative perceptions or doubts about the competence of a sponsor or CRO might lead to a loss of current or potential investment, impacting liquidity and R&D capabilities.
  7. Cost of Public Relations and Reputation Management: Addressing negative publicity or restoring reputation may involve hiring PR firms, running new communication campaigns, or other measures that come with their own costs.
  8. Additional Regulatory Submission Fees: If there’s a need to submit additional data or modifications due to labeling errors, it might come with additional regulatory submission fees.
  9. Lost Revenue: In cases where the error affects a trial’s outcome or delays the approval of a market-ready drug, lost revenue from sales can be significant, especially if the drug in question is expected to be a blockbuster.
  10. Termination of Partnership Agreements: If the sponsor or CRO has partnerships or agreements with other entities (like co-development or licensing agreements), severe errors might lead to renegotiations or terminations.

  

While not all of these consequences can be attributed to labeling errors directly, they illustrate the potential repercussions of any missteps. It underscores the importance of attention to detail, quality control, and robust risk management strategies in all aspects of clinical trials, including labeling.

Conclusion

There is no doubt the world of clinical trials labeling is complex and there is no room for error when it comes to managing the safety, financial, and reputational risks that are at stake. Working with a proven, knowledgeable, and experienced labeling partner can help assure your project meets the high-quality standards required for a successful trial.

In this post we’ve defined what clinical labels are, looked at the importance of quality in clinical trial labeling, and the ramifications of errors caused by poor quality or lack of attention to detail. In our next post we’ll dive deeper into the challenges of getting clinical trial labeling right and discuss strategies for assuring your project is a success.

In the meantime, you can learn more about the different applications of clinical trial label booklets here. 

 
1 https://www.history.com/topics/ancient-greece/achilles
2 https://www.centerwatch.com/articles/25453-mid-study-updates-delay-trials-at-least-a-month-csdd-report-finds
3 https://www.federalregister.gov/documents/2021/03/16/2021-05370/potential-medication-error-risks-with-investigational-drug-container-labels-public-meeting-request